<DOC>
	<DOC>NCT02905695</DOC>
	<brief_summary>The aim of this placebo-controlled clinical trial is to assess the effectiveness of the local infiltration of the analgesic Chirocaïne® on perineal pain after episiotomy or first-degree tear. The pain intensity is measured in immediate postpartum period by using a numerical rating scale (NRS) at the following times: H2, H4, H8, H12, H24, H36, H48 during rest, defecation and during activities. The safety of Chirocaïne® and the patient satisfaction are also evaluated at each time.</brief_summary>
	<brief_title>Post-partum Perineal Pain - Chirocaine®</brief_title>
	<detailed_description />
	<mesh_term>Levobupivacaine</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>Patients aged 1845 years Single pregnancy. Vaginal normal birth in cephalic presentation or assisted vaginal delivery by vacuum extractor. Patients having a mediolateral episiotomy or a firstdegree perineal tear, epidural analgesia. Patients affiliated to a national insurance scheme Patients who have given their written consent Patient not speaking, reading, writing French. Multiple pregnancy. Breech delivery or instrumental delivery by forceps or spatula. Intact perineum. No epidural analgesia. Patient who represent contraindication to local anesthetics, severe arterial hypotension. Previous tear requiring sutures.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Post-partum Perineal pain</keyword>
	<keyword>Episiotomy</keyword>
	<keyword>First-degree tear</keyword>
</DOC>